Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial

Lancet

Volumn 357, Issue 9272, 2001, Pages 1915-1924

  Simoons, Maarten L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GLYCERYL TRINITRATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; TICLOPIDINE; TROPONIN I; TROPONIN T;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; BLEEDING; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035897893     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)05060-1     Document Type: Article

References (35)

1. Acute coronary syndromes: Unstable angina and non-Q wave myocardial infarction
2. The challenge of acute coronary syndromes
3. Coronary plaque disruption
4. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
5. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients: Angiographic results from the CAPTURE trial
6. Coronary angioscopic findings in the infarct-related vessel within 1 month acute myocardial infarction: Natural history and the effect of thrombolysis
7. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
8. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
9. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis
10. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
11. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
12. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
13. Benefit of abciximab in patients with refractory unstable angina in relation to serum Troponin T levels
14. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban
15. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
16. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes
17. Thrombolysis in Myocardial Infarction (TIMI) Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in subjects treated with recombinant tissue plasminogen activator and streptokinase
18. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
19. Myocardial infarction redefined: A consensus document
20. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes
21. Long-term treatment with a platelet glycoprotein receptor antagonist after percutaneous coronary revascularization
22. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) Trial
23. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
24. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial
25. The use of oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: Why are the results so disappointing so far?
26. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study
27. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina
28. Effects of abxicimab, ticlopidine and combined abxicimab/ticlopidine therapy on platelet and leucocyte function in patients undergoing coronary angioplasty
29. Efficacy of abciximab induced platelet blockade using a rapid point of care assay
30. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
31. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
32. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotin IIb/IIIa blockade
33. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
34. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)
35. Clinical benefit of platelet glycoprotein IIb/IIIa blockade with coronary stenting in acute myocardial infarction